Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

70.61
Delayed Data
As of Jun 24
 -2.03 / -2.79%
Today’s Change
51.82
Today|||52-Week Range
75.12
+2.65%
Year-to-Date
BMY Regular Dividend: BMY will begin trading ex-dividend on 06/29/16 with a $0.38 dividend payable to shareholders of record as of 07/01/16.
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Jun 22 / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
7 Profitable Medical Stocks Ranked as Buys Now
Jun 21 / Zacks.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
3 Ways This $30 Billion Market Is Bristol's for the Taking
Jun 21 / MotleyFool.com - Paid Partner Content
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Jun 22 / Zacks.com - Paid Partner Content
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Jun 21 / Zacks.com - Paid Partner Content
Cramer: Let's Put Brexit in Its Historic Context
Jun 22 / TheStreet.com - Paid Partner Content
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Jun 21 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close72.64
Today’s open70.56
Day’s range70.53 - 71.85
Volume7,414,129
Average volume (3 months)6,042,326
Market cap$118.9B
Dividend yield2.15%
Data as of 4:04pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)-22.50%
Earnings growth (this year)+25.84%
Earnings growth (next 5 years)+21.20%
Revenue growth (last year)+4.29%
P/E ratio75.4
Price/Sales6.97
Price/Book8.30

Competitors

 Today’s
change
Today’s
% change
SNYSanofi-2.74-6.65%
NVONovo Nordisk-2.34-4.38%
GSKGlaxoSmithKline-1.76-4.14%
ABBVAbbVie-1.45-2.37%
Data as of 4:06pm ET, 06/24/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.66
Annual revenue (last year)$16.6B
Annual profit (last year)$1.6B
Net profit margin9.45%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Giovanni Caforio
Chief Financial Officer &
Executive Vice President
Charles A. Bancroft
Corporate headquarters
New York, New York

Forecasts

Partner Offers

Search for Jobs